Each module exists because the literature ties it directly to glaucoma progression or quality-of-life outcomes. Voice-guided, calibrated to the patient's screen and distance, recorded longitudinally.
01 · Visual field
Catch the silent loss.
Peripheral-vision damage is the diagnostic signature of glaucoma — and the patient never feels it until 30–40% of axons are gone. A 24-2 screening grid done at home, voice-guided, reveals scotomas months before the next office visit.
Heijl A et al · Acta Ophthalmologica · 2009
02 · Visual acuity
Track central vision over years.
Glaucoma usually preserves central acuity until late, which is why acuity tracking matters: it captures advanced disease, comorbid cataract or AMD, and post-surgical recovery. ETDRS-equivalent Snellen, calibrated to the screen, voice-guided answers.
Bailey IL & Lovie JE · AJOO · 1976 (chart standard)
03 · Contrast sensitivity
The earliest functional signal.
Glaucoma damages contrast perception well before visual-field defects show up — patients describe lights as dim, halos around streetlights, struggling at dusk. A Pelli-Robson-equivalent test caught this years before automated perimetry.
Hawkins AS et al · Ophthalmic Physiol Opt · 2003
04 · External eye / surface
Drops fail when the surface is raw.
Chronic preservative-containing drops damage the ocular surface; the patient can't tolerate them, stops, and progression accelerates. Smartphone anterior-segment photos catch hyperaemia and blepharitis early so prescribing can switch to preservative-free before adherence collapses.
Baudouin C et al · Prog Retin Eye Res · 2010
05 · Quality of life
What treatment actually feels like.
The validated NEI VFQ-25 captures the functional impact of vision loss before structural tests catch up — driving difficulty, falls, reading speed, social withdrawal. Required by FDA for clinical-trial endpoints. Filled out every 90 days inside the app.
Mangione CM et al · Arch Ophthalmol · 2001 (NEI VFQ-25)
06 · Drops & adherence
The only lever that always works.
OHTS proved IOP-lowering halves five-year progression. Real-world adherence is ~50%. We schedule each drop, send daily check-ins via email, log every dose, and surface adherence trends to the doctor — turning the highest-leverage variable into a measurable one.
Kass MA et al · Arch Ophthalmol · 2002 (OHTS) · Friedman 2007